Noncoding RNAs as novel immunotherapeutic tools against cancer

Kaur, Maninder; Kaur, Bhavneet; Konar, Monidipa; Sharma, Sadhna

doi:10.1016/bs.apcsb.2021.11.011

Cited by 3 publications

(3 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The composition and functionality of the tumor immune microenvironment differ across cancer types. Tumor immune microenvironment predominantly consists of DCs, lymphocytes (e.g., B cells, CD4 + T cells and CD8 + T cells), myeloid cells (e.g., macrophages, MDSCs and neutrophils) and NK cells ( 123 ). Tumor immune microenvironment participates in regulating cancer immune evasion and response to immunotherapy.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Wang,

Yu,

2023

Front. Immunol.

View full text Add to dashboard Cite

The increasing knowledge in the field of oncoimmunology has led to extensive research into tumor immune landscape and a plethora of clinical immunotherapy trials in cancer patients. Immunotherapy has become a clinically beneficial alternative to traditional treatments by enhancing the power of the host immune system against cancer. However, it only works for a minority of cancers. Drug resistance continues to be a major obstacle to the success of immunotherapy in cancer. A fundamental understanding of the detailed mechanisms underlying immunotherapy resistance in cancer patients will provide new potential directions for further investigations of cancer treatment. Noncoding RNAs (ncRNAs) are tightly linked with cancer initiation and development due to their critical roles in gene expression and epigenetic modulation. The clear appreciation of the role of ncRNAs in tumor immunity has opened new frontiers in cancer research and therapy. Furthermore, ncRNAs are increasingly acknowledged as a key factor influencing immunotherapeutic treatment outcomes. Here, we review the available evidence on the roles of ncRNAs in immunotherapy resistance, with an emphasis on the associated mechanisms behind ncRNA-mediated immune resistance. The clinical implications of immune-related ncRNAs are also discussed, shedding light on the potential ncRNA-based therapies to overcome the resistance to immunotherapy.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Wang,

Yu,

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Since ncRNAs have the ability to regulate gene expression, protein translation and growth pathways, they can regulate a variety of cellular processes, such as growth, differentiation and drug resistance, which are highly related to the occurrence and development of cancer (99). Furthermore, non-coding RNAs, particularly microRNAs (miRNAs/miRs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), can regulate the expression of immune genes, such as PD-L1, in a variety of tumors, thereby serving an important role in immunotherapy (100).…”

Section: Regulation Of Pd-l1 Expression In Solid Tumors By Non-coding...mentioning

confidence: 99%

Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)

Wang

et al. 2022

Int J Oncol

View full text Add to dashboard Cite

Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have achieved marked and durable efficacy in patients with different solid tumors and have improved their survival. However, the presence of primary or acquired resistance to immune checkpoint blockades results in only a small fraction of patients benefiting from the treatment. An increasing number of preclinical studies have reported that PD-L1 expression in tumor cells is involved in a number of epigenetic changes, including histone modifications, non-coding RNA regulation and DNA methylation. In addition, multiple epigenetic targeting drugs have been demonstrated to directly or indirectly interfere with PD-L1 expression in various cancer models. This provides opportunities to better characterize the regulatory mechanisms of PD-L1 expression and explore novel therapeutic strategies to improve immunosuppressant response rates and overcome drug resistance. The present review focuses on the latest findings and evidence on the epigenetic mechanism regulating PD-L1 expression and discusses the biological and clinical implications of this regulatory mechanism in solid tumors. A rational combination of epigenetic regulation and PD-1/PD-L1 axis blockade may improve the prognosis of patients with solid tumors.

show abstract

“…LncRNA NEAT1-associated aerobic glycolysis in prostate cancer could blunt tumor immunosurveillance by T cells ( Xia et al, 2022 ). Furthermore, lncRNAs could be used as novel immunotherapeutic tools against cancer, and immunotherapy based on lncRNAs could increase the effectiveness and reduce off-target effects ( Kaur et al, 2022 ). Together, lncRNA plays a role in diagnosing, prognosis, and treating BC ( Rodríguez bautista et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

A lactate-related LncRNA model for predicting prognosis, immune landscape and therapeutic response in breast cancer

Jia

Zhang²,

Li³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Breast cancer (BC) has the highest incidence rate of all cancers globally, with high heterogeneity. Increasing evidence shows that lactate and long non-coding RNA (lncRNA) play a critical role in tumor occurrence, maintenance, therapeutic response, and immune microenvironment. We aimed to construct a lactate-related lncRNAs prognostic signature (LRLPS) for BC patients to predict prognosis, tumor microenvironment, and treatment responses. The BC data download from the Cancer Genome Atlas (TCGA) database was the entire cohort, and it was randomly assigned to the training and test cohorts at a 1:1 ratio. Difference analysis and Pearson correlation analysis identified 196 differentially expressed lactate-related lncRNAs (LRLs). The univariate Cox regression analysis, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis were used to construct the LRLPS, which consisted of 7 LRLs. Patients could be assigned into high-risk and low-risk groups based on the medium-risk sore in the training cohort. Then, we performed the Kaplan–Meier survival analysis, time-dependent receiver operating characteristic (ROC) curves, and univariate and multivariate analyses. The results indicated that the prognosis prediction ability of the LRLPS was excellent, robust, and independent. Furthermore, a nomogram was constructed based on the LRLPS risk score and clinical factors to predict the 3-, 5-, and 10-year survival probability. The GO/KEGG and GSEA indicated that immune-related pathways differed between the two-risk group. CIBERSORT, ESTIMATE, Tumor Immune Dysfunction and Exclusion (TIDE), and Immunophenoscore (IPS) showed that low-risk patients had higher levels of immune infiltration and better immunotherapeutic response. The pRRophetic and CellMiner databases indicated that many common chemotherapeutic drugs were more effective for low-risk patients. In conclusion, we developed a novel LRLPS for BC that could predict the prognosis, immune landscape, and treatment response.

show abstract

Noncoding RNAs as novel immunotherapeutic tools against cancer

Cited by 3 publications

References 111 publications

Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)

A lactate-related LncRNA model for predicting prognosis, immune landscape and therapeutic response in breast cancer

Contact Info

Product

Resources

About